Document is current
Any future updates will be listed below
-
Authors
Willrich, Maria Alice V. https://orcid.org/0000-0002-9318-7091
Murray, David L. https://orcid.org/0000-0003-1720-335X
Rajkumar, S. Vincent https://orcid.org/0000-0002-5862-1833
Bryant, Sandra C.
Larson, Dirk https://orcid.org/0000-0002-2970-2124
Pazdernik, Vanessa
Snyder, Melissa R.
Kyle, Robert A.
Dispenzieri, Angela https://orcid.org/0000-0001-8780-9512
- License Information
-
More Information
Article History
Received: 11 April 2022
Revised: 2 August 2022
Accepted: 18 August 2022
First Online: 2 September 2022
Conflict of interest
: This study was sponsored by Sebia Inc. (Lisses, France). The sponsor had no role in the data analysis. Additional funding to the Mayo Clinic includes grants numbers: P01 CA062242/CA/NCI NIH HHS, P50 CA100707/CA/NCI NIH HHS, R01 CA083724/CA/NCI NIH HHS, R01 CA107476/CA/NCI NIH HHS, R01 CA168762/CA/NCI NIH HHS, P50 CA186781//CA/NCI NIH HHS, JABBS foundation and Predolin foundation. AD and MAVW participated in an advisory board for Myeloma360 in 2021. The authors declare no other conflict of interest pertaining to this work.
